Share this video  

ASCO GI 2021 | Key updates from ASCO GI 2021

Philippe Merle, MD, PhD, Croix-Rousse Hospital, Lyon, France, updates on key trials that wil be presented at this years upcoming American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, including the updated overall survival results of the IMbrave150 study (NCT03434379), evaluating atezolizumab and bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).